A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2006
10/11/2006	CN1844120A Aryl piperazine modified benzo [b] thiophene compounds and their preparation method and use
10/11/2006	CN1843497A Compound ledebouriella root granula technology for treating drug-addict
10/11/2006	CN1843496A Composition for preventing and treating aphrenia
10/11/2006	CN1843493A Externally applied medicine for relieving pain and preparation method thereof
10/11/2006	CN1843488A Granula and its preparation method
10/11/2006	CN1843474A Medicine composition and method for the production thereof
10/11/2006	CN1843461A Pharmaceutical composition, its preparation method and quality control method
10/11/2006	CN1843437A Medicinal composition for treating insomnia and its preparing process
10/11/2006	CN1843432A Quality control method for traditional Chinese medicine formulation for treating generalized anxiety
10/11/2006	CN1843425A Dispersion tablet for getting brain and heart unobstructed and preparation method and its quality control method
10/11/2006	CN1843393A Use of pharmaceutical composition containing aceglutamide and safflower
10/11/2006	CN1843353A Use of AR-A014418 in preparing medicine for preventing and treating nerve degenerative diseases
10/11/2006	CN1279054C Type I cytokine receptor TCCR
10/11/2006	CN1279053C Modulators for beta-amyloid peptide aggregation comprising D-amino acids
10/11/2006	CN1279041C Diazabicyclo alkane derivatives with NK1 antagonistic activity
10/11/2006	CN1279040C Tryasolyl tropane derivatives for therapy
10/11/2006	CN1279026C Prostaglandin endoperoxide H synthase biosynthesis inhibitors
10/11/2006	CN1278736C Novel dopaminergic neuron protective factor, and its application
10/11/2006	CN1278734C Pharmaceutical composition for stopping drug addiction and its preparing process
10/11/2006	CN1278728C Intelligence-developing, heart-nourishing, mind-tranquilizing and digestion-aiding oral liquid
10/11/2006	CN1278696C Pharmaceutical use of asafetida
10/11/2006	CN1278694C Preparation method of medicine powder for curing epilepsy
10/11/2006	CN1278683C Use of dipeptidyl peptidase IV inhibitor in preparing medicine for treating anxiety neurosis
10/11/2006	CN1278681C Adduct of topiramate and tramadol hydrochloride and uses thereof
10/10/2006	US7119207 NK-1 receptor antagonists, (e.g., substance P receptor antagonists)
10/10/2006	US7119203 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
10/10/2006	US7119201 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
10/10/2006	US7119196 Anxiolytic agents with reduced sedative and ataxic effects
10/10/2006	US7119186 Nucleotide sequences coding polypeptide for use in the treatment of spinocerebellar ataxia
10/10/2006	US7119165 Nogo receptor-mediated blockade of axonal growth
10/10/2006	US7119122 Compounds for the inhibition of nitric oxide synthase
10/10/2006	US7119118 90-95% eicosapentaenoic acid (EPA) and < 5% of docosahexaenoic acid (DHA); treating psychiatric or central nervous disorders
10/10/2006	US7119117 Tocopherol enriched compositions and amelioration of inflammatory symptoms
10/10/2006	US7119116 Direct aminolysis of a carbamate ester or hydrolysis to an acid followed by coupling with an amine; analgesics, disorders of eating, nervous system, psychology, sleep, urogenital, respiratory and gastrointestinal systems; antiischemic, anticarcinogenic, antiinflammatory agents, antiallergens
10/10/2006	US7119113 optionally halogenated N-(trifluoromethyloxazol-2-yl)xanthene-9-carboxamides; treatment of neurological disorders such as Alzheimer's disease and dementia
10/10/2006	US7119111 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
10/10/2006	US7119109 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
10/10/2006	US7119107 Pyridone derivatives
10/10/2006	US7119104 Alpha-(oxy-, sulfo- or amino-)[3-(imidazolyl, oxazolyl or thiazolyl)alkylene(indazolyl, benzisoxazolyl or benzisothiazolyl)]acetic acids, esters or alkali salts
10/10/2006	US7119097 2-(4,6-dimethoxypyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid; formulations for oral, parenteral, or nasopharyngeal delivery; endothelin receptor antagonist
10/10/2006	US7119092 Chemical compounds
10/10/2006	US7119087 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof
10/10/2006	US7119086 Affinity and selectivity for arginine-vasopressin and/or ocytocin receptors; synthesis
10/10/2006	US7119085 Inhibit amyloid protein deposits
10/10/2006	US7119083 novel 2-(azetidin-2-on-1-yl)alkanedioic acid esters and amides useful for treating disease states that are associated with and responsive to antagonism of a vasopressin V1a receptor in a mammal
10/10/2006	US7119081 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
10/10/2006	US7119066 Replacing cysteine 17 with alanine, glutamine 63 with arginine and a deletion of the terminal 15 amino acid residues; treatment of huntington's disease, obesity, and gestational or adult onset diabetes
10/10/2006	US7119063 Alzheimer's disease therapy; polypeptides
10/10/2006	US7118903 Comprises genetically engineered protein for use in treatment and prevention of cancer, obesity, cardiac, vascular, neurologic and or aging disorders
10/10/2006	US7118890 Antibodies to vertebrate delta proteins and fragments
10/10/2006	US7118730 Quinoline derivative as diagnostic probe for disease with tau protein accumulation
10/10/2006	CA2418778C Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
10/10/2006	CA2352554C Substituted benzimidazoles and their use as parp inhibitors
10/10/2006	CA2350734C 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
10/10/2006	CA2336000C N-substituted piperazines and 1,4-disubstituted piperidines
10/10/2006	CA2306333C Oral morphine multiparticulate formulation
10/10/2006	CA2212887C Monoclonal antibody specific for .beta.a4 peptide
10/10/2006	CA2211889C Vasoconstrictive substituted 2,3-dihydro-1,4-dioxinopyridines
10/10/2006	CA2207323C Use of pramipexole as a neuroprotective agent
10/05/2006	WO2006105313A2 Compositions of and methods of using oversulfated glycosaminoglycans
10/05/2006	WO2006105019A1 Compounds and methods for treating seizure disorders
10/05/2006	WO2006104791A1 O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
10/05/2006	WO2006104400A1 Copper antagonist compositions
10/05/2006	WO2006104396A1 Pre-complexed copper antagonist compositions
10/05/2006	WO2006104280A1 Prophylactic/therapeutic agent for diabetes
10/05/2006	WO2006104099A1 RORα PROMOTING THE INDUCTION OF Bmal1 EXPRESSION
10/05/2006	WO2006103551A1 Controlled release formulations of oxycodone
10/05/2006	WO2006103546A2 Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands
10/05/2006	WO2006103511A1 Cyclopentapyridine and tetrahydroquinoline derivatives
10/05/2006	WO2006103463A1 Iron modulators
10/05/2006	WO2006103401A2 N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use
10/05/2006	WO2006103342A2 Indanyl-piperazine derivatives, method for preparing same and pharmaceutical compositions containing same
10/05/2006	WO2006103316A1 Food composition for binding acetaldehyde in mouth and in digestive track, and method for the preparation of the composition
10/05/2006	WO2006103261A2 Inhibitors of neurotrypsin and determination thereof
10/05/2006	WO2006103255A1 Imidazopyridine derivatives useful as inos inhibitors
10/05/2006	WO2006103116A1 Human antibodies with beta-amyloid peptide-binding capacity and their applications
10/05/2006	WO2006103088A1 Novel hydroxyethylamine and ketone compounds having asp2 inhibitory activity
10/05/2006	WO2006103038A1 Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
10/05/2006	WO2006102958A1 Substituted aminoalkyl- and amidoalkyl-benzopyran derivatives
10/05/2006	WO2006102933A1 Preparation of autologous haematopoietic stem cells, the methods of production, cyropreservation and use for therapy of traumatic diseases of the central nervous system
10/05/2006	WO2006102750A1 Combined-step process for pharmaceutical compositions
10/05/2006	WO2006090273A3 [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
10/05/2006	WO2006072458A3 Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
10/05/2006	WO2006069097A3 Nicotinic alpha-7 receptor ligands and preparation and uses thereof
10/05/2006	WO2006066049A3 Humanized antibodies that recognize beta amyloid peptide
10/05/2006	WO2006055747A3 Bis(thio-hydrazide amides) for increasing hsp70 expression
10/05/2006	WO2006047196A3 Cgrp receptor antagonists
10/05/2006	WO2006015124A3 Fused ring heterocycle kinase modulators
10/05/2006	WO2005092392A3 Conjugated psychotropic drugs and uses thereof
10/05/2006	US20060223984 Gamma-conopeptides
10/05/2006	US20060223891 Use of alverine, alone or in combination with a tricyclic antidepressant or an antidepressant which is a specific inhibitor of serotonin reuptake for treatment of depression
10/05/2006	US20060223890 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
10/05/2006	US20060223888 Valproic acid analogues and pharmaceutical composition thereof
10/05/2006	US20060223886 Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
10/05/2006	US20060223885 Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
10/05/2006	US20060223881 Use of gamma- tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
10/05/2006	US20060223871 Thiophene-and thiazolesulfonamides as antineoplastic agents
10/05/2006	US20060223868 Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1)
10/05/2006	US20060223861 Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
10/05/2006	US20060223857 Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression

1 ... 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 ... 1833